# Comparative Evaluation of HMG Family Proteins and miR-106a-5p in Low-Grade Non-Invasive and High-Grade Muscle-Invasive Papillary Urothelial Carcinoma

**Authors:** Natalia Domian, Magdalena Smereczańska, Małgorzata Mrugacz, Grzegorz Młynarczyk, Irena Kasacka

PMC · DOI: 10.3390/ijms27052089 · International Journal of Molecular Sciences · 2026-02-24

## TL;DR

This study compares the expression of HMG proteins and miR-106a-5p in low- and high-grade bladder cancers, finding distinct patterns that may help in diagnosis and prognosis.

## Contribution

The study reveals distinct expression patterns of HMG proteins and miR-106a-5p in low- and high-grade urothelial carcinoma, suggesting their potential as biomarkers.

## Key findings

- HMGA1 and HMGB1 were reduced in low-grade tumors but increased in high-grade tumors.
- miR-106a-5p levels were highest in normal tissue and significantly reduced in high-grade cancers.
- HMGA2 showed minimal expression in low-grade tumors but partial restoration in high-grade tumors.

## Abstract

Urothelial carcinoma (UC) of the bladder exhibits low- and high-grade papillary forms with distinct prognoses. High mobility group proteins (HMGA1, HMGA2, HMGB1) and miR-106a-5p are involved in tumor progression, but their interplay in UC remains incompletely understood. The aim of this study was to compare the expression of these parameters in low- and high-grade papillary UC. Tissue samples from 80 patients (40 low-grade and 40 high-grade) undergoing transurethral resection or cystectomy were analyzed, with control samples consisting of tumor-adjacent tissues without histopathological alterations obtained from the same patients. HMGA1, HMGA2, and HMGB1 protein expression was assessed immunohistochemically. Gene expression was quantified by real-time PCR, and miR-106a-5p levels were measured by droplet digital PCR. Statistical analysis was conducted using Statistica 13.3, applying one-way ANOVA with Tukey’s post hoc test and correlation analysis, with p < 0.05 considered significant. Expression of HMGA1 and HMGB1 was reduced in low-grade papillary urothelial carcinoma compared to control tissues, whereas both proteins were significantly increased in high-grade lesions. HMGA2 expression was minimal in low-grade tumors but partially restored in high-grade tumors. Analysis revealed the highest levels of miR-106a-5p in normal urothelium, slightly decreased in low-grade tumors, and significantly reduced in high-grade cancers. HMG proteins and miR-106a-5p demonstrate distinct expression patterns in low- versus high-grade papillary UC, which correlates with tumor aggressiveness. These molecules may serve as diagnostic and prognostic biomarkers. Their potential as therapeutic targets requires further mechanistic and translational investigation.

## Linked entities

- **Genes:** HMGA1 (high mobility group AT-hook 1) [NCBI Gene 3159], HMGA2 (high mobility group AT-hook 2) [NCBI Gene 8091], HMGB1 (high mobility group box 1) [NCBI Gene 3146]
- **Proteins:** HMGA1 (high mobility group AT-hook 1), HMGA2 (high mobility group AT-hook 2), HMGB1 (high mobility group box 1)
- **Diseases:** urothelial carcinoma (MONDO:0040679), bladder cancer (MONDO:0004986)

## Full-text entities

- **Genes:** HMGA1 (high mobility group AT-hook 1) [NCBI Gene 3159] {aka HMG-R, HMGA1A, HMGIY}, HMGB1 (high mobility group box 1) [NCBI Gene 3146] {aka HMG-1, HMG1, HMG3, SBP-1}, HMGA2 (high mobility group AT-hook 2) [NCBI Gene 8091] {aka BABL, HMGI-C, HMGIC, LIPO, SRS5, STQTL9}
- **Diseases:** UC (MESH:D014523), Papillary Urothelial Carcinoma (MESH:D002291), cancers (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12984743/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12984743/full.md

## References

33 references — full list in the complete paper: https://tomesphere.com/paper/PMC12984743/full.md

---
Source: https://tomesphere.com/paper/PMC12984743